COVID-19 mRNA Vaccines and Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
The Coronavirus Disease 2019 (COVID-19) messenger RNA (mRNA) vaccines, BNT162b2 and mRNA-1273, manufactured by Pfizer-BioNTech and Moderna, respectively, received the United States Food and Drug Administration (FDA) emergency use authorization in December 2020 and have since been widely administered. Recognizing the increased mortality risk from COVID-19 in cancer patients, the major cancer scientific societies such as the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), and National Comprehensive Cancer Network (NCCN) generally recommend COVID-19 vaccination in cancer patients if there are no contraindications. However, patients with active cancer were excluded from the landmark vaccine trials. In addition, immune checkpoint inhibitors (ICIs) now constitute the contemporary standard-of care systemic regimens across various cancer types. Therefore, there is a concern regarding the risk of immune-related adverse events (irAEs) after administration of COVID-19 mRNA vaccines in patients with cancer treated with an ICI, albeit there is paucity of data.
European Journal of Cancer , éditorial en libre accès, 2020